MW 519.3 Da, Purity >98%. Kinase inhibitor, commonly used as a protein kinase A inhibitor (IC50 = 135 nM). Also inhibits other kinases, including MSK1 , S6K1 and ROCKII (IC50 values are 120, 80 and 270 nM, respectively).
AKT, AKT2_HUMAN, AKT3 kinase, AKT3_HUMAN, DKFZp434N0250, HIHGHH, KAPCA_HUMAN, KIAA0619, MPPH, Oncogene AKT2 protein kinase B beta, PKA C-alpha, PKA C-beta, PKACA, PKACB, PKB, PKB beta, PKB-GAMMA, PKBB, PKBG, PPNAD4, PRKACA, PRKACAA, PRKACB, PRKBB, PRKBG, Protein kinase A catalytic subunit, Protein kinase A catalytic subunit alpha, Protein kinase A catalytic subunit beta, Protein kinase Akt-2, Protein kinase Akt-3, Protein kinase B beta, Protein kinase B gamma, Protein kinase cAMP dependent catalytic beta, Protein kinase, cAMP dependent, catalytic, alpha, RAC-BETA, RAC-PK-beta, RAC-PK-gamma, RAC-beta serine/threonine-protein kinase, RAC-gamma, RAC-gamma serine/threonine-protein kinase, ROCK2_HUMAN, ROK alpha, Rho associated coiled coil containing protein kinase 2, Rho associated, coiled coil containing protein kinase II, Rho kinase 2, Rho-associated, Rho-associated protein kinase 2, Rock II, Rock2m, STK-2, Serine threonine protein kinase Akt 3, V akt murine thymoma viral oncogene homolog 3 (protein kinase B, gamma), V akt murine thymoma viral oncogene homolog 3 protein kinase B gamma, V-AKT murine thymoma viral oncogene homolog 2, V-AKT murine thymoma viral oncogene homolog 3, cAMP dependent protein kinase alpha catalytic subunit, cAMP dependent protein kinase beta catalytic subunit, cAMP dependent protein kinase catalytic subunit alpha, isoform 1, cAMP-dependent protein kinase catalytic beta subunit isoform 4ab, cAMP-dependent protein kinase catalytic subunit alpha, cAMP-dependent protein kinase catalytic subunit beta, coiled-coil-containing protein kinase 2, murine thymoma viral (v-akt) homolog-2, p164 ROCK-2, rac protein kinase beta
MW 519.3 Da, Purity >98%. Kinase inhibitor, commonly used as a protein kinase A inhibitor (IC50 = 135 nM). Also inhibits other kinases, including MSK1 , S6K1 and ROCKII (IC50 values are 120, 80 and 270 nM, respectively).
Kinase inhibitor, commonly used as a protein kinase A inhibitor (IC50 = 135 nM). Also inhibits other kinases, including MSK1 , S6K1 and ROCKII (IC50 values are 120, 80 and 270 nM, respectively).
AKT3 also known as Protein Kinase B gamma is a serine/threonine kinase that plays an important role in cell survival and metabolism. Along with AKT2 a closely related isoform AKT3 shares structural similarities but differs in tissue distribution and specific functions. AKT3 has a molecular weight of approximately 56 kDa. It is expressed in brain heart and testis tissues. Its catalytic activity is regulated by phosphorylation at two key residues contributing to its activation state.
AKT3 and AKT2 influence processes like glucose uptake cell proliferation and suppression of apoptosis. These proteins do not form a stable complex but interact with other proteins as part of their activation and signaling processes. The cAMP Protein Kinase Catalytic subunit often called PKA C or PKAc is involved in similar pathways regulating numerous cellular processes through phosphorylation events. ROCK2 or Rho-associated coiled-coil containing protein kinase 2 acts in cytoskeletal dynamics influencing cell shape and movement.
AKT3 participates in the PI3K/AKT signaling pathway important for transmitting extracellular signals into the cell influencing growth and survival. In this pathway AKT3 and AKT2 interact with proteins like mTOR and GSK-3 which help regulate cell cycle progression and metabolism. ROCK2 is mainly involved in the RhoA/ROCK pathway modulating actin cytoskeleton organization and affecting processes such as contraction cell migration and proliferation.
AKT3 and AKT2 have been linked to cancer and insulin resistance. Mutations or aberrant activation can lead to excessive cell growth and survival contributing to tumorigenesis. Similarly dysregulation of AKT3 and AKT2 signaling can cause insulin resistance affecting glucose homeostasis. ROCK2 is connected to cardiovascular diseases influencing blood vessel tone and heart function. These proteins by being integral to these disease pathways present potential therapeutic targets and the use of kinase inhibitors like those targeting AKT and ROCK pathways can modulate their activity in disease contexts.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120341, H89 dihydrochloride, Kinase inhibitor
Normal human melanocytes (NHMs) were treated with ab120341 at the indicated concentrations to test if the inhibition of MSK1 activation results in the down-regulated MITF and EDNRB expression in UVB-exposed NHMs. ab120341 was added immediately after UVB irradiation and cells were cultured for 6h (for MITF, A) or 24 h (for EDNRB, B). Total mRNAs were purified and Real-time RT-PCR was carried out with MITF or EDNRB primer and β-actin primer as the internal control. Error bars represent S.D. from triplicate experiments. *P<0.05 and **P<0.01 against NHMs UVB-irradiated in the absence of H89, respectively.
Tagashira, Hideki et al., PLOS One., 10(6):e0128678. Fig 8.; doi: 10.1371/journal.pone.0128678.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com